News

The Canadian drug deliver maker said that the approval, if accorded, will allow it to market and distribute the buccal insulin spray product in India as ‘Oral Recosulin’.

The NX02-0020 study participants included 192 repeatedly treated men, who were a part of completed NX02-0014 and NX02-0016 Phase 2 trials or taking part in the NX02-0017 and

Study 3072, second of three, Phase III studies, has not achieved statistical significance to meet primary endpoint although numerical improvement was established. The study was designed to determine

The partnership will allow manufacturing organizations to achieve a competitive advantage by turning detailed production data into actionable information that can be accessed from any internet-connected device including

The approval forms part of the company’s strategy to develop Gablofen prefilled syringe for reducing preparation steps, helping to simplify the pump refill process for patients receiving ITB

The partnership will leverage the accelerator mass spectrometry (AMS) technology to remove pharmacokinetic uncertainty and offer drug developers early bioavailability data, thus enabling to overcome the limitations of

Kaneq Bioscience was created for developing a protein tyrosine phosphatase1B (PTP-1B) inhibitor, designed for treating type 2 diabetes mellitus. Kaneq Pharma CEO Daniel Bouthillier said other approaches targeting

The agreement allows Dezima to in-license CETP inhibitor from Mitsubishi Tanabe Pharma and supports the advancement of DEZ-001 into Phase 3 trials. Professor John Kastelein, founder of Dezima,

The Nijmegen facility will produce ADCs, which combine specific anti-cancer antibody or antibody fragment to an anti-cancer therapeutic, required for Phase III trials and early launches. Company has